Guidance
1.1 Paclitaxel in combination with a platinum therapy (cisplatin or carboplatin) should be the standard initial therapy for patients with ovarian cancer following surgery.
1.2 The use of paclitaxel/platinum combination therapy in the treatment of recurrent (or resistant) ovarian cancer is recommended if the patient has not previously received this drug combination. If the patient has already received both drugs, the combination of paclitaxel and platinum-based therapy in recurrent (or resistant) ovarian cancer is not recommended, outside the context of clinical trials.